Amgen (AMGN) has been displaying a dynamic profile in the market, with the valuation of its shares closely following analyst targets. Some entities, such as QRG Capital Management, have cut their stock position. Conversely, Pinnacle Financial Partners, Global Wealth Management Investment Advisory, and several others have increased their stakes. Amgen has drawn investor attention, especially with regard to its obesity drug, MariTide. Meanwhile, the company's stock has showed varying performance, moving in opposition to general market trends at times. Distinctly positive developments include strong pipeline momentum contributing to Amgen's potential rally towards 2025 and HSBC turning more bullish on the company into 2026. Additionally, JP Morgan Health conference, Amgen's increasing dividend, and a $650M US manufacturing expansion indicate extensive progress. However, some Wall Street analysts have trimmed the price target citing policy risks, while Amgen's valuation is under reassessment following a 28% one-year share price gain.
Amgen AMGN News Analytics from Fri, 18 Jul 2025 07:00:00 GMT to Sat, 17 Jan 2026 13:13:18 GMT -
Rating 6
- Innovation 4
- Information 5
- Rumor -1
